Progress in the Management of Paediatric-Onset Multiple Sclerosis.
demyelination
disease-modifying treatment
neurocognitive
neurodisability
relapse
Journal
Children (Basel, Switzerland)
ISSN: 2227-9067
Titre abrégé: Children (Basel)
Pays: Switzerland
ID NLM: 101648936
Informations de publication
Date de publication:
09 Nov 2020
09 Nov 2020
Historique:
received:
30
09
2020
revised:
01
11
2020
accepted:
06
11
2020
entrez:
13
11
2020
pubmed:
14
11
2020
medline:
14
11
2020
Statut:
epublish
Résumé
Considerable progress has been made in the understanding and treatment of paediatric-onset multiple sclerosis (POMS); how this has translated into more effective care is less well understood. Here, we evaluate how recent advances have affected patient management and outcomes with a retrospective review of POMS patients managed at two paediatric neuroimmunology centres. Two cohorts, seen within a decade, were compared to investigate associations between management approaches and outcomes. Demographic, clinical and neurocognitive data were extracted from case notes and analysed. Of 51 patients, 24 were seen during the period 2007-2010 and 27 during the period 2015-2016. Median age at onset was 13.7 years; time from symptom onset to diagnosis was 9 months. Disease-modifying therapies were commenced in 19 earlier-cohort and 24 later-cohort patients. Median time from diagnosis to treatment was 9 months for earlier vs. 3.5 months in later patients (
Identifiants
pubmed: 33182341
pii: children7110222
doi: 10.3390/children7110222
pmc: PMC7695340
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mult Scler. 2012 May;18(5):679-82
pubmed: 22013145
Ann Neurol. 2020 Jul;88(1):42-55
pubmed: 32267005
Lancet. 2018 Apr 21;391(10130):1622-1636
pubmed: 29576504
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
J Neurol Neurosurg Psychiatry. 2020 May;91(5):483-492
pubmed: 32132224
Neurology. 2018 Oct 23;91(17):e1579-e1590
pubmed: 30258022
Arch Neurol. 2009 Jan;66(1):54-9
pubmed: 19139299
Neurology. 2014 Oct 14;83(16):1432-8
pubmed: 25217060
Neurology. 2007 Apr 17;68(16 Suppl 2):S7-12
pubmed: 17438241
Mult Scler. 2013 Sep;19(10):1261-7
pubmed: 23572237
Arch Dis Child. 2015 Jul;100(7):623-9
pubmed: 25552262
Med Care. 2001 Aug;39(8):800-12
pubmed: 11468499
JAMA Neurol. 2018 Apr 1;75(4):478-487
pubmed: 29305608
Neuropediatrics. 2012 Aug;43(4):174-5
pubmed: 22911479
Mult Scler. 2012 Jan;18(1):116-27
pubmed: 22146610
Neurology. 2020 Mar 10;94(10):e1040-e1050
pubmed: 31919112
Neurology. 2019 May 28;92(22):e2538-e2549
pubmed: 31043474
Lancet Neurol. 2020 Apr;19(4):307-316
pubmed: 32199096
N Engl J Med. 2018 Sep 13;379(11):1017-1027
pubmed: 30207920
Lancet Neurol. 2014 Sep;13(9):936-48
pubmed: 25142460
Arch Neurol. 2009 Aug;66(8):967-71
pubmed: 19667217
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Med Care. 1999 Feb;37(2):126-39
pubmed: 10024117
Mult Scler. 2017 Aug;23(9):1179-1187
pubmed: 28381105
Ann Neurol. 2012 Aug;72(2):211-23
pubmed: 22926854
Clin Neurol Neurosurg. 2008 Nov;110(9):897-904
pubmed: 18534742
Mult Scler. 2019 Jan;25(1):72-80
pubmed: 28933245
Neurology. 2016 Aug 30;87(9 Suppl 2):S82-7
pubmed: 27572867
Mult Scler. 2016 Mar;22(3):354-61
pubmed: 26041802
Neurology. 2018 Nov 6;91(19):e1778-e1787
pubmed: 30333163
Dev Med Child Neurol. 2019 Sep;61(9):1039-1049
pubmed: 30932181
J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):141-7
pubmed: 23154123